Haemonetics Corp [HAE] stock prices are up 1.25% to $84.04 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The HAE shares have gain 4.85% over the last week, with a monthly amount glided 1.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Haemonetics Corp [NYSE: HAE] stock has seen the most recent analyst activity on December 15, 2025, when Needham downgraded its rating to a Hold. Previously, Citigroup downgraded its rating to Neutral on December 11, 2025, and kept the price target unchanged to $88. On August 11, 2025, downgrade downgraded it’s rating to Outperform but maintained its price target of $78 on the stock. Barrington Research reiterated its Outperform rating and decreased its price target to $86 on August 08, 2025. JP Morgan downgraded its rating to a Neutral but $62 remained the price target by the analyst firm on August 08, 2025. Citigroup upgraded its rating to Buy for this stock on July 09, 2025, but kept the price target unchanged to $90. In a note dated June 26, 2025, Robert W. Baird initiated an Outperform rating and provided a target price of $87 on this stock.
The stock price of Haemonetics Corp [HAE] has been fluctuating between $47.31 and $87.32 over the past year. Currently, Wall Street analysts expect the stock to reach $87 within the next 12 months. Haemonetics Corp [NYSE: HAE] shares were valued at $84.04 at the most recent close of the market. An investor can expect a potential return of 3.52% based on the average HAE price forecast.
Analyzing the HAE fundamentals
The Haemonetics Corp [NYSE:HAE] reported sales of 1.33B for trailing twelve months, representing a drop of -5.27%. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.19 and Total Capital is 0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 82.33 points at the first support level, and at 80.62 for the second support level. However, for the 1st resistance point, the stock is sitting at 85.93, and for the 2nd resistance point, it is at 87.82.
Ratios To Look Out For
It’s worth pointing out that Haemonetics Corp [NYSE:HAE]’s Current Ratio is 1.64. On the other hand, the Quick Ratio is 1.03, and the Cash Ratio is 0.54. Considering the valuation of this stock, the price to sales ratio is 2.96, the price to book ratio is 4.63 and price to earnings (TTM) ratio is 24.52.
Transactions by insiders
Recent insider trading involved KROLL MARK W, Director, that happened on Nov 10 ’25 when 1400.0 shares were purchased. Former Officer, Llorens Josep completed a deal on Jun 26 ’25 to buy 18630.0 shares. Meanwhile, Former Officer Strong Stewart W bought 708.0 shares on Jun 12 ’25.
